Magnetic seizure therapy matches ultrabrief ECT in bipolar depression, with less memory loss

Design

Double-blind, randomised, parallel-group pilot trial

Population

55 adults with bipolar depression (45 with an adequate treatment course)

Primary outcome

Clinical remission (24-item HAM-D) and autobiographical memory change

Effect

Remission 30% ECT vs 20% MST; memory decline 22.2% vs 7.1%

Electroconvulsive therapy works in bipolar depression but is held back by fear of cognitive harm. This double-blind pilot randomised 55 patients with bipolar depression to right unilateral ultrabrief ECT or magnetic seizure therapy (MST), treating to remission or a maximum of 21 sessions.

Among the 45 who received an adequate course, remission was similar: 6 of 20 (30%) with ECT and 5 of 25 (20%) with MST. The difference was in memory. A clinically important fall in autobiographical memory, a 25% or greater drop on the Autobiographical Memory Test, occurred in 22.2% after ECT versus 7.1% after MST. Other clinical outcomes were comparable.

The signal is that MST may deliver ECT-like antidepressant effect in bipolar depression with less autobiographical memory disruption, which is the harm patients most often cite in refusing ECT. This is a small pilot, so it supports further study and cautious interest, not a change in first-line practice.

• Double-blind pilot randomising 55 patients with bipolar depression to ultrabrief ECT or magnetic seizure therapy.
• Remission was similar: 30% (6/20) with ECT and 20% (5/25) with MST among adequately treated patients.
• Clinically important autobiographical memory decline occurred in 22.2% after ECT versus 7.1% after MST.
• Other clinical outcomes were comparable between the two treatments.
• Treat as hypothesis-supporting for MST, not a reason to change first-line practice yet.

Why it matters

Cognitive side effects, not efficacy, are the usual reason patients decline ECT, so a comparably effective option with less memory harm would matter.

Don't overread it

This was a small pilot explicitly described as preliminary; it cannot establish equivalence or that MST is safer overall.

The statistics, in plain English

With only 45 adequately treated patients, the remission difference (30% vs 20%) is well within chance; the memory comparison is more striking but still from a small sample, so the estimate is imprecise.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.